Y-mAbs Therapeutics (YMAB) PT Raised to $48 at BofA Securities Due to Potential Best-in-Class Therapies
Tweet Send to a Friend
BofA Securities analyst Ying Huang raised the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $48.00 (from $41.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
